Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P M Battezzati

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Journal of the American College of Cardiology|January 12, 2001
Heart rate variability and early recurrence of atrial fibrillation after electrical cardioversionF Lombardi, A Colombo, B Basilico, et al.
Hepatology (Baltimore, Md.)|February 1, 1991
Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response studyA Crosignani, P M Battezzati, K D Setchell, et al.
Journal of Hepatology|March 1, 1993
Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBCP M Battezzati, M Podda, F B Bianchi, et al.
Hepatology (Baltimore, Md.)|May 1, 1997
Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosisP Invernizzi, A Crosignani, P M Battezzati, et al.
Alimentary Pharmacology & Therapeutics|April 1, 1997
Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover studyA Larghi, A Crosignani, P M Battezzati, et al.
Clinical and Experimental Immunology|December 9, 1998
Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody statusP Invernizzi, P M Battezzati, A Crosignani, et al.
Hepatology (Baltimore, Md.)|September 1, 1994
Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosisM Camisasca, A Crosignani, P M Battezzati, et al.
Gut|April 25, 2006
Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosisM Allocca, A Crosignani, A Gritti, et al.
Hepatology (Baltimore, Md.)|October 1, 1992
Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response studyC Colombo, A Crosignani, M Assaisso, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 26, 2008
Acute liver and renal failure during treatment with buprenorphine at therapeutic doseM Zuin, A Giorgini, C Selmi, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Journal of the American College of Cardiology|January 12, 2001
Heart rate variability and early recurrence of atrial fibrillation after electrical cardioversionF Lombardi, A Colombo, B Basilico, et al.
Hepatology (Baltimore, Md.)|February 1, 1991
Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response studyA Crosignani, P M Battezzati, K D Setchell, et al.
Journal of Hepatology|March 1, 1993
Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBCP M Battezzati, M Podda, F B Bianchi, et al.
Hepatology (Baltimore, Md.)|May 1, 1997
Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosisP Invernizzi, A Crosignani, P M Battezzati, et al.
Alimentary Pharmacology & Therapeutics|April 1, 1997
Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover studyA Larghi, A Crosignani, P M Battezzati, et al.
Clinical and Experimental Immunology|December 9, 1998
Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody statusP Invernizzi, P M Battezzati, A Crosignani, et al.
Hepatology (Baltimore, Md.)|September 1, 1994
Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosisM Camisasca, A Crosignani, P M Battezzati, et al.
Gut|April 25, 2006
Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosisM Allocca, A Crosignani, A Gritti, et al.
Hepatology (Baltimore, Md.)|October 1, 1992
Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response studyC Colombo, A Crosignani, M Assaisso, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 26, 2008
Acute liver and renal failure during treatment with buprenorphine at therapeutic doseM Zuin, A Giorgini, C Selmi, et al.
Pageof 5